Clinical Trial Update: Study of URC102 to Assess the Safety and Efficacy in Gout Patients [Phase 2]

View source ↗

Summary

A Phase 2 study of URC102 by JW Pharmaceutical evaluated safety and efficacy in patients with gout and hyperuricemia. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• URC102 (URC102)

Snippet

Sponsor: JW Pharmaceutical | Conditions: Gout, Hyperuricemia | Phase 2 | Status: COMPLETED